Hologic (Hologic) Cash, Cash Equivalents, Marketable Securities : $1,932 Mil (As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Hologic Cash, Cash Equivalents, Marketable Securities?

Hologic's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($2,765.00 Mil) to Sep. 2023 ($2,722.50 Mil) but then stayed the same from Sep. 2023 ($2,722.50 Mil) to Dec. 2023 ($1,932.10 Mil).

Hologic's annual cash, cash equivalents, marketable securities increased from Sep. 2021 ($1,170.30 Mil) to Sep. 2022 ($2,339.50 Mil) and increased from Sep. 2022 ($2,339.50 Mil) to Sep. 2023 ($2,722.50 Mil).

Hologic Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Hologic's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hologic Cash, Cash Equivalents, Marketable Securities Chart

Hologic Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

601.80

701.00

1,170.30

2,339.50

2,722.50

Hologic Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															2,441.30	2,582.20	2,765.00	2,722.50	1,932.10

Hologic Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Hologic (NAS:HOLX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Hologic Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Hologic's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hologic (Hologic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (NAS:HOLX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

HOLX:Mexico HO1:Germany HOLX:Austria

Address

250 Campus Drive, Marlborough, MA, USA, 01752

Website

http://www.hologic.com

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Executives

Charles J Dockendorff	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Scott T Garrett	director	35 CROSBY DRIVE, BEDFORD MA 01730
Stephen P Macmillan	director, officer: President and CEO	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Essex D Mitchell	officer: Div. President, GYN Surgical	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Nanaz Mohtashami	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jennifer M Schneiders	officer: President, Diag. Solutions	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Benjamin Jordan Cohn	officer: Principal Accounting Officer	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Stacey D. Stewart	director	5920 WALHONDING ROAD, BETHESDA MD 20816
Elisabeth A Hellmann	officer: SVP, Human Resources	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kevin R Thornal	officer: Div. President, Diagnostics	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
John M. Griffin	officer: General Counsel	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Karleen Marie Oberton	officer: Corp. VP, Finance & Acconting	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Erik S Anderson	officer: Div. Pres., Breast & Skeletal	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jan Verstreken	officer: Group President, International	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Allison P Bebo	officer: SVP, Human Resources	250 CAMPUS DRIVE, MARLBOROUGH MA 01752